Q8IXJ6 (SIR2_HUMAN) Homo sapiens (Human)

NAD-dependent protein deacetylase sirtuin-2 UniProtKBInterProSTRINGInteractive Modelling

389 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5); 3 identical sequences: Pan troglodytes: K7BWL3, A0A6D2Y4Q4; Gorilla gorilla gorilla: G3QJ69

Available Structures

40 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Sirt2 in complex with a 13-mer trifluoroacetylated Ran peptide
5fyq
 Heteromer
P62826; 		56-356
1×SO4; 1×ZN;
Assess
Human SIRT2 in complex with myristoylated peptide (H3K9myr)
4y6l
 Heteromer
P68431; 		56-355
1×ZN;
Assess
Human SIRT2 in complex with 2-O-myristoyl-ADP-ribose
4y6q
 Heteromer
56-355
4×ZN; 4×OMR;
Assess
Human SIRT2 in complex with myristoylated peptide (TNF-alphaK20myr)
4y6o
 Heteromer
P01375; 		57-355
1×ZN;
Assess
Crystal structure of SIRT2 with FAM-PEG4-H4K16(myristoyl) peptide
8tgp
 Heteromer
P62805; 		57-355
1×ZN; 1×MYR;
Assess
Crystal structure of Sirt2-ADPR at an improved resolution
5d7o
homo-2-mer55-355
2×ZN; 2×AR6; 1×PGE;
Assess
Human SIRT2 in complex with small molecule 359
7t1d
homo-2-mer56-356
2×ZN; 4×SO4; 7×EDO; 2×DMS; 2×E7K;
Assess
Crystal structure of human Sirt2 in complex with a brominated 2nd generation SirReal inhibitor and …
5dy4
homo-2-mer56-356
2×ZN; 2×5GN; 2×NAD;
Assess
Crystal structure of human Sirt2 in complex with a SirReal probe fragment
5dy5
homo-2-mer56-356
2×ZN; 2×5GR; 2×EDO; 2×EPE; 2×BU3;
Assess
Structure of human Sirtuin 2 in complex with a selective thienopyrimidinone based inhibitor
5mat
homo-2-mer56-356
2×ZN; 1×7KJ; 14×SO4; 1×PG4; 1×P6G;
Assess
Structure of human SIRT2 in complex with ADP-ribose
3zgv
homo-2-mer55-355
2×ZN; 6×ACT; 2×AR6; 1×GOL; 1×PGE;
Assess
Crystal structure of human Sirt2 in complex with ADPR and EX-243
5d7p
homo-2-mer56-355
2×ZN; 2×AR6; 4×OCZ; 1×PEG;
Assess
Human Sirt2 in complex with ADP ribose and nicotinamide
4rmj
homo-2-mer56-355
2×AR6; 1×NCA; 1×PEG; 3×EDO; 1×NA; 2×ZN; 1×PGE;
Assess
Crystal structure of human Sirt2 in complex with ADPR and CHIC35
5d7q
homo-2-mer56-355
2×ZN; 2×AR6; 4×4I5;
Assess
SIRT2(56-356) with covalent intermediate between mechanism-based inhibitor Glucose-TM-1beta and 1'-…
6nr0
homo-2-mer56-355
2×ZN; 2×KXJ; 2×KXG; 4×NA; 2×SO4; 4×GOL;
Assess
Re-refined structure of the human Sirt2 apoform
3zgo
monomer34-356
1×ZN; 1×P6G; 1×PGE; 1×EDO;
Assess
HUMAN SIRT2 HISTONE DEACETYLASE
1j8f
monomer34-356
1×ZN;
Assess
Crystal structure of human Sirtuin 2 in complex with a selective inhibitor
5y5n
monomer34-356
1×ZN; 1×8NO;
Assess
Sirt2 in complex with a myristoyl peptide
4x3o
monomer52-355
1×ZN; 2×EDO; 1×3Y0;
Assess
Sirt2 in complex with a myristoyl peptide
4x3p
monomer52-355
1×ZN; 1×EDO; 1×CNA; 1×3LX;
Assess
Sirtuin 2 protein with H3K18 myristoylated peptide and intact NAD molecule
6l66
monomer52-355
1×ZN; 1×NAD; 1×3LX;
Assess
Sirtuin 2 demyristoylation native intermediate I & II mixture
6l71
monomer53-355
1×NCA; 1×YOY; 1×YDD;
Assess
Human SIRT2 catalyse short chain fatty acyl lysine
5g4c
monomer54-355
1×ZN; 1×CNA;
Assess
Crystal Structure of SIRT2 in complex with the macrocyclic peptide S2iL5
4l3o
monomer55-356
1×ZN; 1×MES;
Assess
Human Sirt2 in complex with SirReal2 and Ac-Lys-H3 peptide
4rmh
monomer56-356
1×ZN; 1×3TE;
Assess
Crystal structure of Sirt2 in complex with selective inhibitor L5C
5yqo
monomer56-356
1×ZN; 1×L5C;
Assess
Crystal structure of Sirt2 in complex with selective inhibitor L55
5yqn
monomer56-356
1×ZN; 1×L55; 1×PEG;
Assess
Crystal structure of Sirt2 in complex with selective inhibitor A2I
5yql
monomer56-356
1×A2I; 1×ZN; 2×BME;
Assess
Crystal structure of human Sirt2 in complex with a triazole-based SirReal
8owz
monomer56-356
1×KZU; 4×EDO; 1×BTB; 2×BU3; 1×ZN; 1×CL;
Assess
Crystal structure of Sirt2 in complex with selective inhibitor A29
5yqm
monomer56-356
1×ZN; 1×A2X; 4×BME;
Assess
Human Sirt2 in complex with SirReal2 and NAD+
4rmg
monomer56-356
1×ZN; 1×3TE; 1×NAD;
Assess
Human SIRT2 in complex with a specific inhibitor, NPD11033
5y0z
monomer56-356
1×ZN; 1×8K9;
Assess
Human SIRT2 crystal structure in complex with BHJH-TM1
4r8m
monomer55-355
1×ZN; 1×3LX;
Assess
Human Sirt2 in complex with SirReal1 and Ac-Lys-OTC peptide
4rmi
monomer56-355
1×ZN; 1×3TK;
Assess
Human SIRT2 in complex with myristoyl thiourea inhibitor, No.23
7bot
monomer56-355
1×ZN; 1×F4R;
Assess
Human SIRT2 in complex with myristoyl thiourea inhibitor, No.13
7bos
monomer56-355
1×ZN; 1×F4R;
Assess
Sirtuin 2 protein with H3K18 myristoylated peptide
6l65
monomer56-355
1×ZN; 1×MYR;
Assess
Structure of human SIRT2 in complex with 1,2,4-Oxadiazole inhibitor and ADP ribose.
5mar
monomer56-355
1×ZN; 1×AR6; 1×7KE; 2×EDO; 5×DMS; 2×GOL;
Assess
Sirtuin 2 demyristoylation native final product
6l72
monomer56-355
1×OMR; 1×ZN;
Assess
Human Sirt2 in complex with ADP-ribose and the inhibitor quercetin
6qcn
monomer57-355
1×ZN; 1×AR6; 1×QUE;
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3zgo.1.Amonomer0.8134-355
1×ZN;99.69
Assess
5y5n.1.Amonomer0.7834-355
1×ZN; 1×8NO;99.07
Assess

6 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 23zgv.1.Amonomer0.8720-318
1×ZN;100.00
Assess
Isoform 33zgo.1.Amonomer0.8214-335
1×ZN;98.14
Assess
Isoform 35y5n.1.Amonomer0.7914-335
1×ZN; 1×8NO;97.83
Assess
Isoform 43zgo.1.Amonomer0.7934-270
1×ZN;97.89
Assess
Isoform 45y5n.1.Amonomer0.7834-270
1×ZN; 1×8NO;97.90
Assess
Isoform 55mar.1.Amonomer0.854-285
1×ZN; 1×AR6; 1×7KE;98.94
Assess